BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib
NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
A Phase II, Single Arm, Open Label, Multi-center Trial of Neoadjuvant Radiation and Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Previously Untreated Locally Advanced, Resectable, HPV Mediated Oropharynx Cancer
DURABLE: Delayed or Upfront brain RAdiotherapy in treatment naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and rEarrangements
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease